Literature DB >> 9815911

Prognostic value of amplification of c-erb-B2 in bladder carcinoma.

U Lönn1, S Lönn, S Friberg, B Nilsson, C Silfverswärd, B Stenkvist.   

Abstract

Amplification of c-erb-B2 is examined in patients with transitional cell bladder carcinoma. In a pilot study we found that the amplification correlated with high tumor grade. Tumor grade is a known prognostic factor. Therefore, we next examined the prognostic value of c-erb-B2 amplification in patients with >16 years of clinical follow-up. The gene copy number was determined, using semiquantitative PCR, in archival formalin-fixed tissues. Twenty-three percent (37/163 patients) showed the amplification. The amplification correlated with grade and stage. Moreover, we found that tumor grade (P < 0.001) and c-erb-B2 amplification (P < 0.001) showed prognostic information for survival. Patients with grade 3 tumors and concomitant c-erb-B2 amplification showed the worst prognosis. Multivariate analysis indicates that grade and c-erb-B2 amplification are independent prognostic factors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9815911

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

Review 1.  Muscle-invasive urothelial bladder cancer: an update on systemic therapy.

Authors:  Hayley Knollman; J Luke Godwin; Rishi Jain; Yu-Ning Wong; Elizabeth R Plimack; Daniel M Geynisman
Journal:  Ther Adv Urol       Date:  2015-12

Review 2.  Neoadjuvant chemotherapy for invasive bladder cancer.

Authors:  Guru Sonpavde; Cora N Sternberg
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

Review 3.  The route to personalized medicine in bladder cancer: where do we stand?

Authors:  Francesco Massari; Chiara Ciccarese; Matteo Santoni; Matteo Brunelli; Alessandro Conti; Alessandra Modena; Rodolfo Montironi; Daniele Santini; Liang Cheng; Guido Martignoni; Stefano Cascinu; Giampaolo Tortora
Journal:  Target Oncol       Date:  2015-01-30       Impact factor: 4.493

4.  Bladder cancer: can we move beyond chemotherapy?

Authors:  Arlene Siefker-Radtke
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

Review 5.  Role of anti-Her-2 therapy in bladder carcinoma.

Authors:  Alvaro Pinto Marín; Enrique Espinosa Arranz; Andrés Redondo Sánchez; Pilar Zamora Auñón; Manuel González Barón
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-06       Impact factor: 4.553

6.  Biomarkers in bladder cancer: present status and perspectives.

Authors:  Wun-Jae Kim; Soongang Park; Yong-June Kim
Journal:  Biomark Insights       Date:  2007-03-27

7.  [Targeted therapy for metastatic bladder cancer].

Authors:  F Vom Dorp; C Börgermann; A Rose; M Becker; H Rübben
Journal:  Urologe A       Date:  2008-10       Impact factor: 0.639

8.  Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy.

Authors:  Surendra B Kolla; Amlesh Seth; Manoj K Singh; Narmada P Gupta; Ashok K Hemal; Prem N Dogra; Rajeev Kumar
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

Review 9.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

Review 10.  Management of bladder cancer: current and emerging strategies.

Authors:  Neeraj Agarwal; Maha Hussain
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.